Category: Uncategorized

Methamphetamine in a feeding substrate can change fly development, but a laboratory timing difference is not automatically a correction for a human time-of-death estimate. A controlled Lucilia sericata experiment reported adult emergence about 24 hours earlier in two exposed groups. It did not validate subtracting or adding 24 hours whenever methamphetamine is detected in a death investigation.

What was exposed and measured?

Parkhideh and colleagues maintained flies at 28°C and 50 ± 10% relative humidity. Eggs were placed on chicken-liver substrates prepared with methamphetamine concentrations of 0, 45, 90 or 180 ng/mg. These were stated substrate preparation concentrations, not measured concentrations in human blood or individual insects.

The report describes four 1,000-g liver groups, further divided into 500-g portions. It does not clearly identify the number of independently replicated rearing units for each treatment. Ten larvae or specimens were randomly selected per treatment at each morphological sampling stage, at 12-hour intervals through 300 hours. Repeated measurements and many insects do not establish a correspondingly large number of independent treatment replicates.

Investigators recorded developmental stage, length and weight, using morphology, scales and calipers. This was not a validated drug-detection assay in larvae. The paper did not provide measured larval methamphetamine concentrations, analytical recovery, detection limits or a conversion from insects to a deceased person’s exposure.

The timing observation was specific

The authors reported adult flies at approximately 260 hours in the 90 and 180 ng/mg groups, compared with 284 hours in controls. They also described earlier progression to pupation. The approximately 24-hour difference concerned these defined groups under the study’s constant conditions.

It did not measure the interval between human death and insect access to a body. Eggs were introduced to prepared food in a laboratory. A developmental-time observation therefore should not be treated as a direct measurement of time since death in a field case.

Smaller insects could nevertheless develop earlier

Compared with controls, the highest-concentration group had a reported mean larval-length reduction of about 1.227 mm and larval-weight reduction of 7.527 mg. Pupal length differed by about 0.665 mm and pupal weight by 7 mg. These were group comparisons, not measurements of drug burden.

The combination matters: smaller size did not necessarily indicate slower progression to adulthood. An age inference based on length or weight alone could therefore differ from one based on stage or emergence timing.

Significant findings did not apply to every comparison

The investigators used a general linear mixed/repeated-measures analysis and Tukey comparisons, with a significance criterion of p < 0.05. The tables report significant control-versus-treatment differences in larval length and larval weight at all three preparation levels.

Pupal length was different: control comparisons at 45 ng/mg (p = 0.096) and 90 ng/mg (p = 0.522) were not significant; the 180 ng/mg comparison was significant (p = 0.004). This qualifies broader wording elsewhere in the paper suggesting all concentrations significantly reduced both larval and pupal length.

Pupal weight differed significantly between controls and each exposed group, but the comparisons among the three exposed groups were not significant. The report also gives nonsignificant pupal-length timing comparisons, including p = 0.555 and 0.398. The findings do not describe a uniform dose response across every stage and endpoint. Entries printed as p = 0.000 indicate reporting precision, not a literal probability of zero.

What limits transfer to decomposed human remains?

The experiment tested one species, one temperature setting, prepared chicken liver and three exposure levels. It did not reproduce fluctuating temperatures, delayed colonization, human tissue distribution, mixtures of drugs or differing decomposition conditions. The authors called for work at other temperatures.

There was also no human validation group establishing the error produced by applying an unexposed growth model to known-time deaths. Unclear independent replication and the absence of measured substrate or insect concentration data further limit a quantitative correction. Behavioral observations about activity and water use do not identify a validated mechanism or a human impairment state.

The defensible forensic use

The study identifies drug exposure as a potential influence on insect development that warrants attention when assessing a minimum postmortem interval. A case-specific evaluation would need the species, collection stage, environmental history, exposure evidence and the developmental reference being used. Methamphetamine detection alone cannot establish a 24-hour error, an ingestion dose or cause of death.

Other research addresses different entomotoxicological questions: weight change without a shorter total development cycle and why a drug-positive larva does not uniquely identify its feeding source. Neither supplies a methamphetamine correction for this experiment.

Primary source

Parkhideh SZ, Forouzesh M, Akhgari M, Akbarzadeh K, Rahimi S, Rafizadeh S, Rassi Y. Impact of Methamphetamine on the Development of the Forensically Important Species Lucilia sericata (Diptera: Calliphoridae). Journal of Arthropod-Borne Diseases. 2024;18(4):356–368. doi:10.18502/jad.v18i4.19341.

A therapeutic plasma range cannot be transferred automatically to postmortem femoral blood. A Finnish study drawing on 57,903 autopsy cases found that drug-specific median blood concentrations often lay outside published therapeutic plasma intervals. Its comparisons provided interpretive context, not a test proving overdose or a formula recovering the concentration during life.

Which cases and specimens contributed?

Launiainen and Ojanperä examined a national forensic laboratory database covering January 2000 through December 2010. The cases represented multiple causes of death, including poisonings, rather than a uniform drug-free control population. The headline total was the number of autopsies with comprehensive drug analysis; each drug had its own smaller number of findings.

The average death-to-autopsy interval was five days. Bodies were kept at approximately 3–5°C after arrival at the morgue. Femoral venous blood collected at autopsy contained 1% sodium fluoride and was stored at 4°C during the laboratory investigation, usually completed within 12 days after the sample arrived.

Those are cohort handling descriptions, not proof that every drug remained stable or every femoral result equaled the concentration at death. Individual premortem comparison samples were not the basis of this study.

Screening and quantitative distributions were different datasets

Urine screening used immunoassays and LC–time-of-flight MS. Blood monitoring used several chromatographic methods, with changes during the 11-year period. GC–MS and LC–MS/MS supplied confirmation and additional determinations. There was no single fixed assay with one detection limit for all 129 reported drugs.

The investigators initially selected drugs detected at least 50 times, including findings reported only as positive below the quantitation limit. Concentration statistics were calculated from numerical results. Some method-specific subsets therefore had fewer than 50 quantified cases. Positive findings and quantified observations should not be treated as identical denominators.

To limit differences caused by changing methods, certain results were drawn only from specified subsets: 53,095 cases for the stated benzodiazepine/nifedipine method period and 23,385 for selected acidic or neutral drugs. The main table gives drug-specific quantitation limits; detailed validation was assigned to supporting information. Neither the overall case count nor laboratory accreditation substitutes for analyte-specific performance.

The “blood/plasma relationship” was not a measured ratio

The authors constructed a descriptive comparison with published therapeutic plasma ranges. If a drug’s postmortem blood median fell within that range, they assigned a relationship of 1. If it fell below the range, they divided by the lower boundary; if above, they divided by the upper boundary.

Consequently, 1 did not mean equal measured blood and plasma concentrations. It was a category for any median inside an interval. Nor were the numerator and denominator paired samples from the same person. Dividing a new autopsy result by this relationship would not produce a validated premortem plasma estimate.

Of 129 drugs, 61 had an assigned relationship of 1, 22 below 1 and 46 above 1. The investigators found no marked correlation with literature volume of distribution. These descriptive results do not establish a drug-by-drug causal mechanism for the observed differences.

Amlodipine illustrates the reference-range problem

For amlodipine, 313 quantified cases had a median femoral concentration of 0.07 mg/L, with a listed quantitation limit of 0.006 mg/L. The published therapeutic plasma range used for comparison was 0.003–0.015 mg/L. Thus, the typical autopsy value in that dataset exceeded the plasma interval’s upper boundary.

That finding warned against labeling an autopsy concentration abnormal solely because it exceeded a living-person plasma reference. It did not prove that 0.07 mg/L is harmless in every death, that all 313 individuals took therapeutic doses, or that a particular driver was unimpaired. The full case remains necessary.

Upper percentiles were not lethal cutoffs

The study reported medians, means and upper percentiles. For many drugs, the means were much higher than the medians, reflecting skewed distributions. A high percentile described where a value sat among the included quantified observations; it did not mark the boundary between survival and death.

The authors separately tabulated the percentage of findings attributed as the principal drug in fatal poisonings. For 36 drugs that proportion exceeded 10%, making those distributions especially unsuitable as purely non-intoxicated reference populations. Co-detected substances, alcohol, tolerance, use patterns and selection could also influence interpretation.

The article’s conclusion contains a conflicting total of 59,903, while its abstract, methods and principal table identify 57,903. The latter is the study population used here. That inconsistency should not be converted into an additional 2,000 cases.

How the database can help

Historical postmortem distributions can identify when an inference depends on an inappropriate plasma comparator. They cannot independently establish dose, impairment, poisoning or the extent of postmortem change in an individual. The sampling site, method period, quantitation limit, numerical denominator and case circumstances need to accompany the reference value.

For complementary evidence, see paired hospital–autopsy comparisons of cardiovascular drugs and limits of ranking redistribution from volume of distribution.

Primary source

Launiainen T, Ojanperä I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Testing and Analysis. 2014;6:308–316. doi:10.1002/dta.1507.

A low postmortem blood methanol result did not reliably represent the brain findings in two treated fatalities. In a three-case report, investigators found much higher brain methanol concentrations after hospital treatment than the corresponding autopsy blood results suggested. The observation supports attention to treatment history and specimen selection; it does not establish a universal brain-to-blood conversion.

Three linked exposures, different survival and treatment

Andresen and colleagues described three men, aged 39, 34 and 44, linked by an investigation of shared methanol ingestion. The first two were admitted to hospital in coma with severe metabolic acidosis. Initial serum methanol concentrations were 5,400 and 7,400 mg/L. Both received ethanol, folic acid, bicarbonate and hemodialysis after detection of the poisoning.

They died four and three days after admission, respectively. The third man was found dead without the hospital treatment described for the other two. This was a descriptive case series with one person in each clinical course, not a randomized comparison of dialysis or a controlled experiment isolating redistribution.

Autopsy measurements differed by tissue

Selected reported postmortem methanol results

Specimen and units	Case 1	Case 2	Case 3
Femoral venous blood, mg/L	5*	228	2,074
Cardiac blood, mg/L	5*	254	2,130
Vitreous humor, mg/L	8*	201	2,122
Brain stem, mg/kg	738	1,008	2,213
Cerebellum, mg/kg	1,828	Not available	1,811

*The paper reports these numbers, but its stated blood detection limit was 15 mg/L and quantitation limit 53 mg/L. The values of 5 and 8 cannot be represented as validated quantitative measurements within those stated limits; the method was validated in serum, with additional uncertainty about performance in other matrices.

Table 2 supplies the 228 mg/L femoral result for case 2; the earlier clinical-course table rounds or reports it as 220 mg/L. Keeping the chosen table and its units explicit avoids creating an apparently exact agreement that the source does not provide.

The untreated case had broadly similar numerical concentrations across several fluids and tissues, while the treated cases showed larger brain–blood differences. Fluid results in mg/L and tissue results in mg/kg should retain their distinct units. The numbers are not evidence that the same conversion applies across brain regions, treatment courses or other deaths.

Collection and analytical performance matter

Autopsy specimens included femoral and cardiac blood, vitreous, urine, cerebrospinal fluid and tissues. Aliquots were placed in capped, sealed glass vials and stored at 4°C for up to 14 days before analysis. The paper does not provide a standardized individual death-to-autopsy interval for every comparison or a storage experiment proving unchanged concentrations across that period.

Methanol and ethanol were measured by headspace gas chromatography with flame-ionization detection, using tertiary butanol as internal standard. This was targeted chromatographic analysis, not an immunoassay or mass-spectrometric drug screen. The serum-validated method used an eight-point daily calibration, reported linearity up to 5,000 mg/L with R² = 0.996, and specified repeat analysis after dilution for initial results above 5,000 mg/L.

Serum validation does not establish equivalent accuracy, recovery or sensitivity in every brain and postmortem fluid specimen. The published low numbers and validation scope are material limits, even though the overall contrast between the reported brain and blood findings prompted the authors’ specimen-selection concern.

Why did brain and blood differ?

The investigators proposed explanations including impaired clearance from brain tissue associated with edema and disturbed blood flow. They also discussed tissue distribution. These were hypotheses; the study did not directly measure cerebral perfusion or experimentally assign the difference to one mechanism.

Hospital treatment had already changed the measured blood course before death. Comparing an initial serum value with later autopsy whole blood therefore combines treatment, elapsed time, different matrices and possible postmortem processes. It does not measure an isolated postmortem redistribution factor.

What can a death investigation conclude?

The authors recommended considering brain methanol testing alongside blood in suspected fatalities with longer survival. Their three cases support that focused concern, especially when earlier clinical evidence documents severe poisoning. They do not show that every low blood result conceals a high brain concentration.

The report also described neuropathological injury, but did not establish a universally diagnostic lesion or a concentration-only rule for causation. It cannot supply contemporary brain-death determination standards, a clinical treatment protocol or an impairment threshold. Related specimen and timing issues appear in the comparison of earlier serum with postmortem chloroquine blood.

Primary source

Andresen H, Schmoldt H, Matschke J, Flachskampf FA, Turk EE. Fatal methanol intoxication with different survival times—Morphological findings and postmortem methanol distribution. Forensic Science International. 2008;179:206–210. doi:10.1016/j.forsciint.2008.05.014.

“Appetite suppression” can combine effects that occur at different times and adapt differently. A 2010 rat experiment found that amphetamine’s immediate effect on feeding persisted across repeated tests, while a later reduction in intake became smaller under one dosing schedule. Alternating the same dose with a higher dose produced a different pattern.

The study concerns food earned during scheduled feeding opportunities in rats. It does not establish a human weight-loss regimen, diagnose withdrawal or show when a person is functionally unimpaired.

How were feeding and exposure controlled?

White, Hundley and White used 24 adult male Wistar rats, divided among three successive experimental conditions of eight animals each. Rats learned to obtain 94-mg food pellets by lever pressing. During testing, one-hour meal opportunities began every three hours under a 12-hour light/dark cycle.

Each animal underwent eight five-day tests. Saline was administered subcutaneously at light onset on day one; saline or d-amphetamine was administered subcutaneously at light onset on day three. D-amphetamine sulfate was prepared with concentrations expressed as amphetamine base.

In the low-dose condition, day-three treatment alternated between saline and 0.5 mg/kg amphetamine. In the higher-dose condition, it alternated between 1.0 and 2.0 mg/kg. A third group always received 1.0 mg/kg on day three. Alternation order was counterbalanced within the alternating groups.

The one-hour feeding windows are important. The experiment measured intake within that schedule rather than unrestricted moment-to-moment eating, and treatment occurred at the beginning of the rats’ normally less active light phase.

What happened immediately after dosing?

All three active doses—0.5, 1.0 and 2.0 mg/kg—abolished intake during the first post-treatment meal opportunity, approximately the second hour after administration. That immediate effect persisted across testing; the investigators did not observe tolerance to it under this protocol.

A dose sufficient to suppress the first meal was therefore not necessarily sufficient to produce the later feeding pattern. The 0.5 mg/kg dose reduced early intake but did not produce the progressive longer-term reduction seen with the two higher doses.

How was the later effect identified?

The researchers compared meal-by-meal intake after amphetamine with intake after the saline baseline treatment, then accumulated those differences over time. With 1.0 and 2.0 mg/kg, the cumulative deficit deepened later in the first post-treatment day, reaching its greatest extent around 20–23 hours.

This approach preserved timing that a single 24-hour food total could obscure. It also distinguished an initial missed meal from additional reductions at later meal opportunities.

The experiment did not measure plasma amphetamine. The authors discussed rat pharmacokinetic literature when considering possible explanations, but those external estimates are not direct concentration measurements from these subjects. A late feeding effect cannot be converted into a human detection window or impairment duration.

Did repeated 1.0 mg/kg exposure produce tolerance?

When 1.0 mg/kg was administered alone across tests, the later cumulative intake deficit was smaller in tests seven and eight than in earlier test pairs. The authors described this as a tolerance-like effect. The immediate abolition of intake at the first meal remained.

When 1.0 mg/kg alternated with 2.0 mg/kg, comparable tolerance to the longer-term effect was not observed. The authors suggested that occasional higher-dose exposure might maintain or augment the later response to the lower dose.

These are comparisons between particular exposure histories. They do not establish that adding a higher dose causes the same result in humans or that failure to detect tolerance proves an effect will persist indefinitely.

Why did baseline intake complicate the interpretation?

Baseline daily intake declined across tests in the 1.0-mg/kg-only group. A smaller drug-versus-baseline difference could therefore partly reflect a lower comparison baseline, rather than solely a reduced capacity of amphetamine to suppress feeding.

The authors explicitly acknowledged this alternative and called for further study. They also reported continuous weight gain in all groups, which prevents reduced intake at selected meals from being equated with demonstrated progressive weight loss.

A power failure lost the first amphetamine-treatment day’s data in the 1.0-mg/kg-only condition. Its earliest paired summary consequently relied on the second amphetamine administration rather than two complete drug days. That missing observation belongs in the interpretation of the early-to-late comparison.

What conclusions remain well supported?

The study separated short- and longer-term feeding effects by their dose thresholds and patterns across repeated exposure. It also showed why the same nominal dose may behave differently after different prior regimens.

Its mechanistic discussion—including possible changes in hunger regulation, conditioned responses and sensitization—was interpretive. These processes were not independently demonstrated by the feeding measurements. The eight-animal groups, sequential conditions, scheduled food access and changing baselines limit broader claims.

For toxicology interpretation, the practical lesson is to specify the outcome, observation period and comparison baseline before declaring tolerance. Adaptation in a late feeding measure does not establish adaptation in immediate feeding, cognition, cardiovascular function or driving performance.

Scientific source

White W, Hundley MB, White IM. The effects of dose and repeated administration on the longer-term hypophagia produced by amphetamine in rats. Pharmacology Biochemistry and Behavior. 2010;97(2):384–391. doi:10.1016/j.pbb.2010.09.008. Full-text author manuscript. Historical original rat experiment.

Buprenorphine or its metabolite appeared in 55 of 2,369 selected unintentional opioid-death records in a Marion County study. That 2.3% figure described detection among people who had died. It was not the probability that a person prescribed buprenorphine would die, nor proof that buprenorphine caused each of the 55 deaths.

How the study population was assembled

Del Pozo and colleagues retrospectively analyzed coroner, death-certificate and toxicology records from Marion County, Indiana, covering January 2015 through December 2021. Testing for buprenorphine and its metabolite began in the contracted laboratories in 2015, so earlier records were excluded.

Among 2,951 unintentional overdose-death records, 2,475 involved detection of an opioid. The authors excluded 101 records when testing was not comprehensive or the testing laboratory was unknown, leaving uncertainty about buprenorphine coverage. Five children younger than 14 were also excluded. The final analytical sample was 2,369 deaths.

These exclusions were designed to make testing coverage more dependable. They also define the population to which the percentage applies. It cannot be relabeled as a percentage of all deaths, all overdoses, all opioid users or all buprenorphine-treated patients.

What counted as a buprenorphine finding?

The 55 cases involved detection of buprenorphine or norbuprenorphine. Describing every case as a measured parent-drug concentration would erase that distinction. The study used blood and urine findings and laboratory reporting thresholds; it did not present a uniform specimen collection site, death-to-collection interval, storage history or analyte-specific validation dataset.

No common quantitative concentration distribution was provided for these 55 cases. The analysis therefore cannot supply a buprenorphine lethal cutoff, compare paired blood sites, measure redistribution, or reconstruct the drug concentration before death. Laboratory detection and the study’s use of the word “involvement” should remain separate from causal attribution.

Most detections occurred with other substances

Of the 55 cases, 51—92.7%—included other substances the authors considered potent and commonly associated with overdose. Fentanyl and related findings were present in 28 cases (50.9%), benzodiazepines in 24 (43.6%), amphetamine in 23 (41.8%) and methamphetamine in 21 (38.2%). These groups overlapped; adding their percentages would not count distinct people.

Co-detection complicates attributing a mixed-drug death to one compound. It does not automatically establish that every detected drug contributed, that one drug was harmless, or that relative pharmacological potency alone identifies the decisive mechanism in an individual case. The authors themselves state that their study could show substances present after death, rather than establish the causes of the overdoses.

Four cases lacked the other potent substances emphasized by the investigators. One involved a reported encephalopathy attribution, another had diabetic ketoacidosis as a contributing cause, one included hydroxyzine and one antidepressants. These were not four experimentally demonstrated deaths caused solely by buprenorphine.

Why a low detection proportion is not a treated-person risk

The study did not count prescriptions, treated patients, dose, adherence or time receiving treatment. Without those exposure denominators, it cannot calculate the risk of death per treated person or compare that risk directly with another treatment. Low prescribing volume could partly explain a low proportion of detections, a possibility the authors acknowledged.

Nor can the data determine whether a particular detected exposure came from prescribed or non-prescribed medication, why it was taken, or whether treatment was protective for that individual. The paper’s broader treatment and policy discussion draws on additional literature; this record analysis alone does not answer every such question.

Scene descriptions were contextual evidence

Case narratives became available from 2016 onward. Mentions of needles, paraphernalia or suspected heroin provided context, but did not chemically confirm the substance used during the fatal incident. The paper’s narrative counts and table entries are not fully consistent, so they should not be promoted into a precise independently reconciled exposure total.

The study also classified some morphine-and-codeine findings without 6-monoacetylmorphine as heroin under its stated rule. That was an operational classification for analysis, not proof that every such result uniquely established heroin as its source.

What the findings support in death review

Buprenorphine-related findings were uncommon in this selected seven-year regional series and usually occurred with other drugs. The useful forensic lesson is to distinguish what was tested, what was detected, which cases entered the denominator and what the complete investigation attributed as contributory.

Detection alone establishes neither impairment nor an isolated cause of death. A related distinction arises when a study applies a “main intoxicant” classification rule, or when death certificates and integrated forensic review produce different poisoning counts.

Primary source

Del Pozo B, Atkins D, Andraka-Christou B, Wightman R, Clark MH, Huynh P, Ray B. Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015–2021. Drug and Alcohol Dependence Reports. 2023;6:100131. doi:10.1016/j.dadr.2023.100131.

A postmortem bile screen can help direct further testing, but its overall percentage agreement can conceal serious identification failures. In a 25-case study, amphetamine screening had 80% agreement with LC–MS/MS yet a negative Cohen’s kappa of −0.07. The results did not justify treating an amphetamine screen as confirmed exposure.

What specimens were compared?

Franzin and colleagues examined bile from 25 forensic cases initially investigated for suspected intoxication or overdose. This was selected casework, not a population prevalence survey or a study of 25 proven drug-caused deaths. The case table included several other recorded circumstances and many undocumented causes.

Approximately 3 mL was aspirated from the gallbladder at autopsy into tubes containing sodium fluoride and potassium oxalate. The authors recommended storage at −20°C without repeated freezing and thawing. That recommendation, based on laboratory experience, was not a prospective stability experiment within this screening comparison. The table reports a median death-to-autopsy interval of 5.5, with an interquartile range of 4–7.25, but does not label the time unit; it should not be converted into a documented uniform collection schedule.

A qualitative immunoassay and a separate confirmation method

The investigators adapted the Randox Evidence MultiStat chemiluminescence immunoassay, designed for other biological fluids, to bile. Preparation included centrifugation and 1:10 dilution in phosphate-buffered saline, followed by the assay’s further dilution steps. Its output was positive or negative relative to a cutoff, not a measured bile concentration. The listed instrumental amphetamine cutoff was 50 ng/mL; that number should remain attached to the stated preparation and instrument rather than be treated as a human toxicity threshold.

All 25 specimens underwent LC–MS/MS, including screen-negative specimens. Confirmation covered 108 drugs and metabolites, used two monitored transitions per analyte and incorporated deuterated internal standards. Bile was diluted 1:100, underwent enzymatic deconjugation and was calibrated using the diluted matrix. Results above the upper quantitation limit were handled by further dilution and calculation using the dilution factor.

The main paper describes linearity, accuracy, precision, detection and quantitation assessment, with detailed analyte-specific data assigned to supplementary tables. Those descriptions do not turn the screening device into a quantitative method. The authors expressly list inability to perform analytical validation of the screening test as a limitation.

Why 80% agreement was misleading for amphetamines

The screening table lists four amphetamine-positive specimens; confirmation lists one. Table 4 reports false-positive and false-negative screening percentages of 16% and 4%, respectively, across the 25-specimen comparison. Together, these entries indicate that the four screening positives did not identify the one confirmation-positive specimen. Agreement came from the 20 specimens negative by both methods.

Cohen’s kappa accounts for agreement expected from the positive and negative frequencies. Its −0.07 value exposed what the 80% headline obscured. The confirmed amphetamine result was reported at 111.0 ng/mL in one bile specimen; it was not a blood concentration or a demonstrated impairment level.

The authors proposed interference from putrefactive amines as an explanation, alongside possible cross-reactivity with other substances. They did not report measuring a particular interfering amine in every discordant specimen or proving the individual cause of each false result. A plausible decomposition mechanism therefore remains distinct from an experimentally identified interferent.

Other classes performed better, with important qualifications

Table 4 reports complete agreement for benzodiazepines, opiates, cocaine/benzoylecgonine, oxycodone, buprenorphine and pregabalin. Some positive groups were very small: oxycodone and buprenorphine each had one confirmed case, and pregabalin had two. Perfect agreement in a small selected set does not guarantee future sensitivity.

For barbiturates, agreement was 96% and kappa 0.65; for cannabinoids, 96% and 0.88. Methadone agreement was reported as 92.2% with kappa 0.84. The paper contains numerical and wording inconsistencies: its cannabinoid screening row totals 26 despite a 25-specimen cohort, the methadone percentages do not map exactly onto 25 specimens, and the discussion’s broad statement that all screening negatives were confirmed conflicts with the amphetamine false-negative entry. These issues limit independent reconstruction; they should not be silently corrected or summarized as flawless performance.

What can a bile finding establish?

This comparison supports using a specified bile screening workflow to guide analyte-specific confirmation, with especially poor amphetamine performance in this dataset. It did not validate conversion from bile to blood, reconstruction of the concentration at death, or a rule assigning cause of death from a positive result.

Keep the matrix, preparation, assay target, cutoff and confirmation findings together. Related examples include screening disagreements in urine and pericardial fluid and the limitations of vitreous screening.

Primary source

Franzin M, Ruoso R, Concato M, Radaelli D, D’Errico S, Addobbati R. Applicability of a Chemiluminescence Immunoassay to Screen Postmortem Bile Specimens and Its Agreement with Confirmation Analysis. International Journal of Molecular Sciences. 2024;25:3825. doi:10.3390/ijms25073825.

A small nervous system can help researchers study a tightly defined drug response, but simplicity does not make it a miniature human impairment test. An experiment in Caenorhabditis elegans found that repeated amphetamine exposure reduced the proportion of worms showing swimming-induced paralysis.

The work established a behavioral model for investigating tolerance. It did not measure human intoxication, dependence, clinical treatment response or a forensic concentration threshold.

What response did amphetamine produce?

Valladares and colleagues used age-synchronized, late-L4-stage worms. Under the assay conditions, untreated animals swam; exposure to amphetamine gradually produced a reversible cessation of swimming, termed swimming-induced paralysis, or SWIP.

Earlier research cited by the investigators had linked this response predominantly to dopamine signaling. The present experiment asked whether repeated exposure reduced the response. It did not itself identify a new molecular mechanism of tolerance.

Groups of 8–12 worms were placed in wells containing 40 microliters of 0.5 mM amphetamine in 200 mM sucrose solution. Controls received the sucrose solution without amphetamine. The 0.5 mM figure is the concentration in the bathing solution, not a measured internal concentration, a plasma concentration or a dose in mg/kg.

How was repeated exposure arranged?

The main protocol used four 10-minute exposures. Between exposures, worms were briefly washed and returned to food-seeded agar plates for recovery periods of 30, 60 and 90 minutes, respectively. Investigators counted animals exhibiting SWIP each minute during a bath.

For the principal repeated-exposure experiment, the methods report 35 trials across 15 days over five weeks, involving 263 amphetamine-exposed and 115 control animals. Multiple observations came from the same repeatedly exposed animals. The animal count, trial count and minute-by-minute observations describe different levels of the design.

Other control and interval experiments used different numbers of animals and trials. Combining every count into one apparent independent sample would misrepresent the evidence.

Did the response decline immediately?

No clear reduction appeared between the first two exposures. At the end of ten minutes, SWIP affected 70 ± 5% of animals during the first exposure and 76 ± 4% during the second. The reported values are means ± standard errors.

The corresponding proportions fell to 42 ± 6% during the third exposure and 27 ± 9% during the fourth. The investigators interpreted the later reduction as tolerance to the amphetamine-induced behavioral response. Control-solution exposures did not produce SWIP over the same observation periods.

The endpoint is the proportion of worms meeting a behavioral definition at a stated time. A lower proportion does not independently establish less drug in the worms or less effect on every biological system.

Could age or repeated swimming explain the reduction?

The researchers included worms that underwent three control-solution exposures before encountering amphetamine for the first time. This comparison preserved the passage of time and repeated assay experience while changing prior drug exposure.

At ten minutes, that late-first-exposure group showed 56 ± 11% SWIP, not significantly different from the 70 ± 5% first-exposure result in the main protocol. It nevertheless showed significantly more SWIP than the group exposed to amphetamine four times.

These controls argue against elapsed age or repeated swimming alone accounting for the observed reduction. They do not establish that every possible physiological or exposure-related explanation was excluded.

Did the interval between exposures matter?

A separate experiment used three exposures separated by ten-minute recovery intervals. Reduced SWIP was still observed after repeated amphetamine exposure, but the difference from control-pretreated animals emerged later during the bath than in the longer-interval experiments.

The authors described longer intervals as more favorable to the observed tolerance pattern. The protocols also differed in elapsed time and exposure sequence, and the shorter-interval experiment was smaller: four trials, with 40 repeatedly amphetamine-exposed worms, 39 control-pretreated worms receiving a final amphetamine bath, and 28 controls.

A smaller p-value in one protocol does not by itself quantify a larger biological effect. These results do not define an interval that can be translated into a human pattern of use.

Was dopamine depletion demonstrated or ruled out?

Neither. The authors reasoned that the stronger reduction after longer recovery intervals did not fit a simple account in which short intervals merely exhausted dopamine stores. They nevertheless acknowledged that dopamine-vesicle turnover had not been established in this model and that further experiments were needed.

The study did not directly measure dopamine stores, internal amphetamine concentrations, transporter activity or receptor adaptation during the repeated-exposure protocol. Assigning the behavioral change to one specific protein would therefore go beyond the reported measurements.

The authors also speculated about whether the adaptation resembled chronic tolerance, given the worm’s short life cycle. That classification was interpretive; the experiment did not reproduce months or years of human exposure.

What is the practical value of the model?

The assay provides a repeatable response that can be paired with future genetic or molecular experiments. It helps make a general question experimentally tractable: which processes change when the same external drug exposure produces a smaller defined behavioral response?

For toxicology readers, the central discipline is to retain the scale and endpoint. A bath concentration, a worm swimming response and human functional impairment are different measurements. Evidence of adaptation in one cannot establish absence of impairment or toxicity in another.

Scientific source

Valladares DT, Kudumala S, Hossain M, Carvelli L. Caenorhabditis elegans as an in vivo model to assess amphetamine tolerance. Brain, Behavior and Evolution. 2020;95(5):247–255; electronically published April 8, 2021. doi:10.1159/000514858. Full-text author manuscript. Historical original invertebrate experiment.

Experiencing a positive effect from amphetamine did not reliably identify people who also liked alcohol or THC in a small controlled study. The investigators expected responses across drug classes to correlate. Most did not, despite clear average effects from the administered drugs.

The result distinguishes a group-average drug effect from the ability to predict an individual’s response to another drug. It does not establish that the drugs lack shared mechanisms, and it was not a test of taking them together.

What was the trial design?

Wardle, Marcus and de Wit studied 24 healthy social drinkers, 12 men and 12 women, aged 21–31 years. Each completed six 5.5-hour laboratory sessions in a randomized, counterbalanced, double-blind, double-dummy design: one session with each active drug and three corresponding placebo sessions. Sessions were separated by at least 48 hours.

The oral doses were 20 mg d-amphetamine in a capsule, 7.5 mg delta-9-tetrahydrocannabinol in a capsule, and alcohol in a beverage at 0.8 g/kg for men and 0.7 g/kg for women. The sex-specific alcohol doses are specified in the methods; compressing the protocol to “0.8 g/kg for everyone” would be inaccurate.

Capsules were given at 11:30 a.m. and beverages consumed over 15 minutes beginning at 12:30 p.m. This staggered schedule aimed to align peak subjective effects around 1 p.m., approximately 90 minutes after the capsule and 30 minutes after drinking began. Active drugs were administered on separate sessions, rather than in combination.

Who does the sample represent?

Participants were selected for light drug use and social drinking, with no lifetime dependence on alcohol, cannabis or stimulants. Eighty-three percent reported lifetime cannabis use; 33% reported lifetime nonmedical stimulant use. They were not a sample of people with stimulant use disorder.

Twenty-eight participants were randomized, and four discontinued: three because of scheduling conflicts and one because of alcohol-related nausea and vomiting. Replacements yielded the final 24-person analyzable sample. The participant count, rather than the number of sessions or questionnaire ratings, is the relevant denominator for the individual-difference analyses.

The trial was registered after enrollment. The authors explained that they initially had not regarded this acute laboratory protocol as a clinical trial. That timing is part of the study’s methodological record.

What did the researchers measure?

Participants rated feeling a drug effect, liking, disliking, feeling high and wanting more on visual analog scales. Investigators compared changes around the planned peak with changes in the nearest paired placebo session. A separate questionnaire assessed drug-related response patterns, including amphetamine-like stimulation.

Using three placebo sessions helped avoid creating artificial correlations by subtracting the same unusual placebo response from every active-drug response. The analysis concerned placebo-adjusted subjective ratings, not blood amphetamine concentrations or an objective measure of impairment.

What happened after d-amphetamine?

Compared with placebo, d-amphetamine increased ratings of feeling a drug effect, liking the effect and wanting more. The reported probabilities were below .001, below .001 and .001, respectively. Its increase in feeling high had p=.004 and was treated as marginal under the investigators’ stricter correction for multiple group-level comparisons.

Those findings describe average responses within this selected sample at one dose. They do not imply that every participant liked amphetamine or wanted another dose, nor do they establish later dependence.

Did the same people respond positively across drugs?

The primary correlations generally failed to support that prediction. For example, placebo-adjusted liking after amphetamine correlated −.131 with liking after alcohol and −.091 with liking after THC. Neither provided evidence of the hypothesized positive cross-drug relationship.

The paper also explored whether people who experienced stimulant-like alcohol effects showed a closer relationship between alcohol and amphetamine stimulation. In the 12-person stimulant-responder subgroup, the correlation was .601, with p=.05; in the other subgroup it was .008. However, the direct comparison between the two correlation coefficients was not significant, p=.14.

That last test matters. A relationship appearing nominally significant in one small subgroup and not another does not establish that the subgroups differ. The authors regarded the finding as preliminary and in need of replication.

Did personality explain a general susceptibility?

No measured personality trait predicted responses across multiple drug types. Exploratory analyses suggested an alcohol-specific relationship involving constraint, a trait related to behavioral control, but did not establish a personality profile that predicted broadly positive responses to all three substances.

The study used multiple comparisons and distinguished corrected significance from marginal findings. Treating every p-value below .05 as equally confirmatory would overstate its exploratory results.

What limits the conclusions?

The sample was small, young and selected. Only one dose of each drug was tested. Alcohol produced stronger overall “feel drug” ratings than the other drugs despite attempts to match intensity. Oral THC responses were especially variable, and oral isolated THC does not reproduce every feature of inhaled cannabis.

Blinding was imperfect: 70.8% identified a stimulant somewhere in the amphetamine session, and 91.7% identified alcohol in its active session. Expectancies and pre-existing preferences could therefore influence subjective ratings. Nonsignificant correlations in 24 people also do not prove that the true relationships are exactly zero.

The study did not assess combined-use safety, driving, later substance use or dependence outcomes. Its useful contribution is narrower: positive average amphetamine effects did not translate into a reliable general predictor of positive responses to other drug classes in this experiment.

Scientific source

Wardle MC, Marcus BA, de Wit H. A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial. PLoS ONE. 2015;10(10):e0140501. doi:10.1371/journal.pone.0140501. Full text. Historical exploratory controlled human experiment.

Stopping a repeated exposure does not necessarily leave a fixed response to a later dose. A 2016 rhesus-monkey study followed cardiovascular responses to methamphetamine challenge over a year after long-term self-administration ended. Early blood-pressure responses were reduced relative to controls; selected responses were enhanced months later.

This was an animal experiment under anesthesia, not a study of human relapse outcomes. Its value lies in showing how tolerance and enhanced responsiveness can vary with time and endpoint. It does not establish a human risk calendar or a safe interval for reuse.

Who was studied, and what did “abstinence” mean?

Vaupel and colleagues began with eight male rhesus monkeys whose methamphetamine self-administration histories ranged from 3.6 to 8.6 years, averaging 5.5 ± 0.7 years. Their reported average daily intakes ranged from 0.40 to 1.20 mg/kg, with a group mean of 0.67 ± 0.08 mg/kg. These were histories of intravenous methamphetamine hydrochloride exposure, not assigned human-equivalent doses.

The control group contained ten drug-naive monkeys. Although the abstract describes age- and gender-matched controls, the methods specify nine males and one female in that group, compared with eight males in the experienced group.

Follow-up began 24–28 hours after the last self-administration session, then continued at 1, 4, 12, 26 and 52 weeks. “Abstinence” meant cessation of the self-administration regimen; the monkeys still received intermittent experimental methamphetamine challenges. It was therefore not a year without any methamphetamine exposure.

Three experienced animals were euthanized for a planned brain-tissue study after week 12. The cardiovascular group consequently fell from eight to five animals at weeks 26 and 52. Each control animal received one methamphetamine challenge.

How were cardiovascular responses measured?

On test days, the monkeys were anesthetized for imaging. Following ketamine induction and a temporary propofol infusion, isoflurane maintained anesthesia. Investigators administered a saline bolus, observed for five minutes, then gave 0.35 mg/kg methamphetamine intravenously and followed physiological responses for 150 minutes.

Blood pressure was measured with an arm cuff; heart rate and other physiological variables were monitored. Plasma methamphetamine and amphetamine were also measured. Echocardiography assessed a smaller subset: four experienced monkeys at approximately three months and five at one year, alongside ten controls.

The saline comparison was limited to the initial five-minute intervals. There was no separate time-matched saline condition covering the entire 150-minute drug time course. The longer analyses principally compared drug responses between the exposure-history groups.

Which early responses suggested tolerance?

On the first day after self-administration ended, the diastolic-pressure response over the initial 20 minutes was 56% lower than the corresponding control response. Peak systolic-pressure increases were also lower: 14 ± 2 mm Hg on day one and 20 ± 4 mm Hg at week one, compared with 37 ± 2 mm Hg in controls. These values are means ± standard errors.

Those findings supported tolerance to selected pressor effects. Early reductions in the heart-rate response did not reach statistical significance. It would therefore overstate the results to say that every cardiovascular endpoint demonstrated early tolerance.

Seven pre-challenge physiological measures did not differ significantly between groups across the study conditions. Similar resting measurements did not imply identical responses to the subsequent drug challenge.

What changed at 12 and 26 weeks?

At week 12, the experienced group showed a more sustained diastolic-pressure response. Averaged over 150 minutes, the increase was 13 ± 3 mm Hg, compared with 4 ± 3 mm Hg in controls, a significant difference after correction for multiple comparisons. The initial 20-minute comparison at that time was not significant.

At week 26, the mean heart-rate increase over 150 minutes was 22 ± 3 beats/minute in the five remaining experienced monkeys, compared with 7 ± 3 beats/minute in controls. This difference also survived correction. The heart-rate response approached control levels by week 52.

The results were not uniform across pressure measures. A week-12 comparison for mean arterial pressure lost significance after multiple-comparison correction, and several later systolic-pressure comparisons were nonsignificant. Preserving those distinctions prevents a selective endpoint from becoming a claim that all cardiovascular responses were amplified.

Did higher plasma methamphetamine explain the enhanced responses?

The measured concentration patterns did not track the timing of the strongest response changes. Plasma methamphetamine exposure, summarized over 180 minutes, was significantly lower at week one, while the largest early pressure reduction occurred on day one. At weeks 12 and 26, enhanced physiological responses occurred without significant plasma methamphetamine differences from controls.

The authors consequently favored a pharmacodynamic explanation rather than a simple increase in circulating methamphetamine. That interpretation is supported by the measured mismatch; it does not exclude every unmeasured biological influence.

What did the echocardiograms add?

At roughly three months, left-ventricular ejection fraction and cardiac output were significantly lower in the experienced subset than in controls. Ejection fraction improved by one year, and the authors described recovery toward control values.

There were no echocardiograms immediately after self-administration ended. The study therefore cannot determine whether the functional reductions first emerged during follow-up or were already present earlier. Four animals at the first examination and five at the second are the relevant denominators, not all eight original subjects at both times.

Why is direct translation to human risk uncertain?

Anesthesia can modify cardiovascular responses. Isoflurane concentrations also changed across follow-up and differed from controls early in the study. The monkeys had heterogeneous prior research histories, including other test compounds; the control group did not reproduce those histories. Later attrition reduced precision just as enhanced responses appeared.

The authors proposed that sensitization might have developed during chronic exposure and become visible as tolerance waned. That mechanism was an interpretation, not a directly demonstrated sequence of cellular events. The study measured responses to a controlled challenge, not clinical heart attacks, sudden deaths or human relapse rates.

The defensible lesson is that exposure history, elapsed time and the selected cardiovascular endpoint can all matter. Early tolerance cannot be treated as lasting protection, and apparent recovery in this small animal cohort cannot establish safety for an individual person.

Scientific source

Vaupel DB, Schindler CW, Chefer S, Belcher AM, Ahmet I, Scheidweiler KB, Huestis MA, Stein EA. Delayed emergence of methamphetamine’s enhanced cardiovascular effects in nonhuman primates during protracted methamphetamine abstinence. Drug and Alcohol Dependence. 2016;159:181–189. doi:10.1016/j.drugalcdep.2015.12.008. Full-text author manuscript. Historical original nonhuman-primate study.

A metabolite can be pharmacologically active without explaining a particular effect at a particular time. In a small rhesus-monkey experiment, plasma amphetamine appeared later than the strongest learned response to methamphetamine. The investigators therefore did not find support for a substantial contribution of the amphetamine metabolite to the discriminative cue they measured.

That conclusion concerns a trained behavioral endpoint under a specific dosing protocol. It does not establish that amphetamine is inactive, identify a human impairment threshold, or turn a methamphetamine-to-amphetamine ratio into a reliable clock.

What did “drug discrimination” mean?

Banks and colleagues studied three adult male rhesus monkeys weighing 6–11 kg. Two were initially experimentally naive; the third had earlier cocaine-discrimination experience, with no drug exposure for at least three months before this training began.

The monkeys learned to respond on one key after methamphetamine and another after saline. Food reinforcement depended on completing a fixed ratio of 30 responses. The training dose initially was 0.1 mg/kg intramuscular methamphetamine, but reliable discrimination was not established after 136 sessions. Investigators increased it to 0.18 mg/kg; criterion performance then took 63–73 sessions.

During tests, either key could produce food. The principal outcome was the percentage of responses on the methamphetamine-associated key, termed methamphetamine-appropriate responding. A value of 90% or more met the study’s definition of full substitution.

This percentage describes learned key selection. It is not a percentage of impairment, a verbal report of intoxication, or a measure of driving performance. Extensive training is part of the experimental context rather than evidence that untrained humans would show the same pattern.

Which drugs, doses and specimens were compared?

The experiments used (+)-methamphetamine hydrochloride and (+)-amphetamine hemisulfate, with doses expressed as their salts. Intramuscular doses of 0.032–0.32 mg/kg were tested. The 0.32 mg/kg dose of each drug was the lowest tested dose producing full substitution in all three monkeys and was selected for the concentration–effect comparisons.

Behavioral tests followed dosing at approximately 3, 10, 30, 56, 100, 180, 300 and 560 minutes. Neither drug significantly changed overall response rate under the tested conditions. Preserving that null finding matters: a change in which key an animal selected was not accompanied by a demonstrated general slowing or acceleration of responding.

Pharmacokinetic experiments used the same three monkeys but occurred on separate days from behavioral testing. Blood collected before dosing and at 3, 10, 30, 56, 100, 180 and 300 minutes was processed to plasma. The study therefore compared corresponding time courses across sessions; it did not measure every behavioral response alongside a simultaneous blood sample.

Did plasma methamphetamine and amphetamine peak together?

No. After 0.32 mg/kg intramuscular methamphetamine, individual peak plasma methamphetamine concentrations ranged from 38.7 to 67.5 ng/mL, with a group mean of 51 ± 8.5 ng/mL, reported as mean ± standard error. The observed peak occurred at 10 minutes in two monkeys and 56 minutes in the third.

The amphetamine metabolite remained below the assay’s detection limit until 56 minutes. Its observed peak occurred at 180 minutes in one monkey and 300 minutes in two. A result below detection is an analytical limit, not proof that absolutely no metabolite was present.

Direct administration of amphetamine was a separate condition. After 0.32 mg/kg intramuscular amphetamine, peak plasma amphetamine concentrations ranged from 31.3 to 42.9 ng/mL, averaging 37.2 ± 3.3 ng/mL. Those figures describe administered amphetamine, not the amount formed as a metabolite after methamphetamine. Confusing the conditions would materially change the interpretation.

What did the delayed metabolite imply about the learned cue?

Methamphetamine-appropriate responding was greatest early, when the amphetamine metabolite was undetectable or low. Later, when metabolite concentrations were highest, responding predominantly occurred on the saline-associated key.

The mismatch argues against a substantial role for the delayed amphetamine metabolite in maintaining this particular methamphetamine cue. Direct amphetamine administration nevertheless produced methamphetamine-appropriate responding. The experiment therefore distinguished the ability of administered amphetamine to substitute for the cue from the contribution of amphetamine formed after methamphetamine.

Other metabolites were not measured. The findings do not exclude every metabolite-related effect, effects under another exposure regimen, or effects on outcomes other than trained key selection.

Why did concentration and effect trace a loop?

When the investigators plotted learned responding against plasma concentration over time, the data formed clockwise hysteresis loops after either methamphetamine or directly administered amphetamine. At a similar plasma concentration, the measured cue could be stronger earlier and weaker later.

The authors interpreted this pattern as consistent with acute tolerance. It shows why a concentration–effect relationship may depend on where a measurement falls within the time course. It does not validate a numerical correction that can be applied to a person’s blood result.

With only three subjects, separate pharmacokinetic and behavioral sessions, and an extensively trained animal endpoint, the evidence cannot establish an individual human concentration–impairment curve. The reported concentrations are plasma values, not interchangeable whole-blood or urine values.

What can this study contribute to toxicology interpretation?

It offers a disciplined way to test a proposed explanation: identify the analyte, measure its timing, define the effect, and ask whether their time courses agree. Here, delayed metabolite formation did not track the strongest drug cue.

A forensic interpretation still needs its own specimen, collection time, analytical limits and functional evidence. Detection of methamphetamine or amphetamine alone does not establish impairment, and the disappearance of a learned animal cue does not establish that all pharmacological effects have ended.

Scientific source

Banks ML, Smith DA, Kisor DF, Poklis JL. Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys. Pharmacology Biochemistry and Behavior. 2016;141:58–65. doi:10.1016/j.pbb.2015.12.001. Full-text author manuscript. Historical original nonhuman-primate experiment.